AI-Driven Biomarker Predicts Optimum Length of Treatment for Prostate Cancer
A biomarker developed with digitalized pathology and artificial intelligence demonstrated it was able to identify which men treated with radiation for high-risk localized prostate cancer could be spared long-term hormone therapy and its potential side effects.
Presenting their findings on June 4 at the American Society of Clinical Oncology meeting, Duke Cancer Institute researchers reported results from a phase 3 trial involving the National Cancer Institute Cooperative Group NRG/RTOG 9202 of the successful AI-derived digital pathology tool.
Angelo Moore, PhD, MSN, RN, NE-BC, director of the DCI Community Outreach, Engagement, and Equity program Office of Health Equity, has been named a Fellow of the American Academy of Nursing (AAN). Moore, along with four other nurses at Duke, is among 253 new fellows selected from across 40 states, the District of Columbia, and 13 countries.
Beyond one's achievements within the nursing profession, fellows are recognized for "engaging with health leaders nationally and globally to improve health and achieve health equity by impacting policy through nursing leadership, innovation, and science."
As a U.S. Army Non-Commissioned Officer, Moore served during three Gulf War campaigns. After subsequently attending, then graduating from Winston-Salem State University, he joined the U.S. Army Nurse Corps. All told, he served more than 25 years on active duty in multiple leadership roles from Germany to Hawaii — earning several service medals, commendation medals, service ribbons, and three bronze service stars. During this time Moore also completed a master’s degree and a doctorate degree in nursing.
Moore retired from the U.S. Army in 2015 as a Lieutenant Colonel, but his service continued in civilian life with his commitment to serve historically underserved communities in the U.S.
Moore joined DCI in May 2019. He oversees, coordinates, and helps design DCI's community impact-projects to reduce disparities in cancer outcomes for patients across North Carolina and beyond.
⇒LEARN MORE about OHE's latest projects
⇒ Read this 2020 profile of Moore: "In Service to Others: On the Battlefield & In the Community."
The Academy will induct the new class of fellows during its annual Health Policy Conference in October. With this honor comes the Fellow of the American Academy of Nursing "FAAN" credential.
The other Duke inductees are: Mariam Kayle, PhD, RN, CCNs ; Mitchell Knisely, PhD, RN, ACNS-BC, PMGT-BC;Staci Reynolds, PhD, RN, ACNS-BC, CCRN, CNRN, SCRN, CPHQ; Ryan Shaw, PhD, RN, ACHIP.
A drug combination that shows little overall survival benefit in white men with advanced prostate cancer has a far greater effect in Black men with the disease, according to interim results from a study led by the Duke Cancer Institute.
The study, called PANTHER and funded by Janssen Pharmaceuticals, administered the hormone therapies apalutamide and abiraterone acetate plus prednisone to parallel groups of Black and white participants with metastatic prostate cancer.
Read the press release.
